MedTrace Logo

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

NCT02127697 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-04-13

No results posted yet for this study

Summary

The study will assess efficacy, safety and tolerability of NVA237 compared to placebo in patients with poorly controlled asthma over 52 weeks of treatment.

Conditions

Interventions

DRUG

NVA237

NVA237 capsules for inhalation, delivered via Concept1 once daily

DRUG

Placebo to NVA237

Placebo to NVA237 delivered via Concept1 once daily

DRUG

salbutamol/ albuterol

Taken as rescue medication

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-05-31
Completion
2017-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02127697 on ClinicalTrials.gov